Literature DB >> 6776402

Treatment of the bleeding tendency in uremia with cryoprecipitate.

P A Janson, S J Jubelirer, M J Weinstein, D Deykin.   

Abstract

We gave cryoprecipitate to six patients with uremia and bleeding times prolonged to more than 15 minutes. After the infusion, all patients had shortened bleeding times; the times of five became normal. In four patients control of major bleeding episodes was attained, and five underwent major surgical or invasive procedures, with good hemostasis. After infusion the time before the nadir of the bleeding time was reached was between one and 12 hours. The bleeding time returned to pretreatment levels by 24 hours after infusion in five patients, and by 36 hours in the other patient. Platelet-aggregation studies before infusion gave normal results in three patients and abnormal results in three. There wasno change after infusion. Before infusion, levels of Factor VIII coagulant activity and Factor VIII von Willebrand activity were normal, Factor VIII-related antigen was increased, and crossed immunoelectrophoresis of Factor VIII-related antigen was normal. Our findings suggest that cryoprecipitate can temporarily correct the bleeding tendency in patients with uremia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776402     DOI: 10.1056/NEJM198012043032302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

1.  Acquired factor VIII inhibitor associated with lung abscess.

Authors:  P S Ganly; J D Isaacs; M A Laffan; C Haslett; J M Hows
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-03

2.  Blood transfusion and haemostatic management in the perioperative period.

Authors:  A J McIntyre
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

3.  Heat treatment in von Willebrand's disease.

Authors:  J R O'Brien; G P Salmon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-10

4.  Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.

Authors:  M J Weinstein; L E Chute; G W Schmitt; R H Hamburger; K A Bauer; J H Troll; P Janson; D Deykin
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 5.  Preoperative evaluation: the assessment and management of surgical risk.

Authors:  K Kroenke
Journal:  J Gen Intern Med       Date:  1987 Jul-Aug       Impact factor: 5.128

Review 6.  Acute renal failure in the intensive care unit. Part 2.

Authors:  H L Corwin; J V Bonventre
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

Review 7.  Desmopressin (DDAVP) and hemostasis.

Authors:  S Lethagen
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

8.  Factor VIII complex in uraemia and effects of haemodialysis.

Authors:  J H Turney; H F Woods; M R Fewell; M J Weston
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-23

9.  Transcatheter embolization in the management of intractable uremic epistaxis.

Authors:  R F Gagnon; B Ballermann; P Bourgouin; M J Herba; M Kaye
Journal:  Can Med Assoc J       Date:  1982-01-15       Impact factor: 8.262

10.  Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients.

Authors:  A Sioulis; P Malindretos; A Makedou; P Makris; D Grekas
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.